STVN Stevanato Group S.p.A. IFRS Annual reports only
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1849853 · Reporting currency EUR
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 1.19B | 1.10B | 1.09B | 983.68M | 843.92M |
| Cost of revenue | 842.41M | 801.72M | 745.46M | 663.88M | 578.51M |
| Gross profit | 343.88M | 302.32M | 339.89M | 319.80M | 265.40M |
| R&D expense | 25.44M | 31.67M | 35.67M | 34.39M | 29.62M |
| SG&A expense | 99.66M | 93.75M | 88.95M | 85.75M | 62.50M |
| Operating income | 198.80M | 161.14M | 200.72M | 192.43M | 162.22M |
| Interest expense | 5.62M | 6.11M | 3.73M | 3.36M | 4.29M |
| Pretax income | 189.11M | 160.29M | 189.55M | 187.64M | 165.67M |
| Income tax | 49.27M | 42.52M | 43.86M | 44.62M | 31.40M |
| Net income | 139.84M | 117.78M | 145.63M | 142.85M | 134.32M |
| EBITDA | — | — | 279.20M | 257.25M | 218.61M |
| EPS (basic) | 0.51 | 0.43 | 0.55 | 0.54 | 0.53 |
| EPS (diluted) | 0.51 | 0.43 | 0.55 | 0.54 | 0.53 |
| Weighted avg. shares (diluted) | 272.96M | 271.15M | 264.98M | 264.70M | 252.69M |
| Balance sheet | |||||
| Cash & equivalents | 130.60M | 98.27M | 69.60M | 228.74M | 411.04M |
| Receivables | 302.69M | 295.95M | 301.77M | 212.73M | 165.26M |
| Inventory | 268.25M | 245.22M | 255.32M | 213.25M | 148.92M |
| Current assets | 943.35M | 880.12M | 861.89M | 845.77M | 865.97M |
| PP&E, netmay include right-of-use assets (IFRS) | 1.39B | 1.25B | 1.03B | 641.40M | 392.72M |
| Goodwill | 49.98M | 49.98M | 49.98M | 47.24M | 47.24M |
| Intangibles | 36.87M | 33.59M | 30.98M | 32.16M | 31.93M |
| Total assets | 2.54B | 2.33B | 2.07B | 1.66B | 1.42B |
| Current liabilities | 535.88M | 477.47M | 574.39M | 462.50M | 338.62M |
| Total liabilities | 1.06B | 924.43M | 938.93M | 663.79M | 577.18M |
| Shareholders' equity | 1.49B | 1.40B | 1.13B | 996.13M | 842.07M |
| Cash flow statement | |||||
| Operating cash flow | 286.08M | 155.78M | 105.21M | 103.31M | 133.34M |
| Capital expenditure | 263.76M | 302.60M | 433.23M | 235.03M | 107.69M |
| Free cash flow | 22.32M | -146.82M | -328.02M | -131.72M | 25.64M |
| Investing cash flow | -272.92M | -310.21M | -421.22M | -242.95M | -96.43M |
| Financing cash flow | 22.06M | 183.22M | 158.03M | -44.54M | 254.85M |
| Depreciation & amortization | — | — | 78.48M | 64.82M | 56.38M |
| Stock-based compensation | — | — | 1.43M | — | — |
| Dividends paid | 14.74M | 14.46M | 14.29M | 13.50M | 11.20M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.